GLUE vs NEO: Which Stock Is the Better Buy?
Monte Rosa Therapeutics, Inc. and NeoGenomics, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — GLUE vs NEO, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Monte Rosa Therapeutics, Inc. (GLUE) | NeoGenomics, Inc. (NEO) | |
|---|---|---|
| Market cap | $1.5B | $1.5B |
| Revenue (latest FY) | $123.67M | $727.33M |
| Net income (latest FY) | $-38.63M | $-108.03M |
| Revenue growth (5y CAGR) | — | 10.4% |
| Net margin | -31.2% | -14.9% |
| Return on equity | -16.6% | -12.9% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 3 |
| Positive free cash flow | No | No |
Verify the comparison
Use the filing period and source shown by each tool before treating two figures as comparable.
See the full GLUE vs NEO breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open GLUE's full financials → Open NEO's full financials →More comparisons
Frequently asked questions
Which is bigger, GLUE or NEO?
NeoGenomics, Inc. is larger by market capitalization — $1.5B versus $1.5B.
Which grows faster, GLUE or NEO?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.